• Explore /
  • Poster
  • / Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.

Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.

Abstract Poster

Authors

Daniel DeAngelo

Daniel J. DeAngelo

Dana-Farber Cancer Institute, Boston, MA

Daniel J. DeAngelo , Elias Jabbour , Matthias Stelljes , Michaela Liedtke , Wendy Stock , Nicola Gökbuget , Giovanni Martinelli , Susan Mary O'Brien , Kongming Wang , Tao Wang , M. Luisa Paccagnella , Barbara Sleight , Erik Vandendries , Anjali S. Advani , Hagop M Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01564784

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7028)

DOI

10.1200/JCO.2016.34.15_suppl.7028

Abstract #

7028

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Elias Jabbour

First Author: Elias Jabbour

First Author: Hagop M Kantarjian

First Author: Marcos J.G. De Lima